A COVID-19 vaccine doesn t magnetize your arm, there was no stand-in for President Biden driving the electric F-150 Lightning pickup truck, and Egypt didn t project Palestinian flags onto the pyramids, Bob Oswald says in his Facts Matter column.
E-Mail
As hospitals, insurance companies and policy makers seek to improve healthcare quality and reduce rising medical costs, one important metric used to assess clinicians hinges on how patients feel about their healthcare experience. Many healthcare providers and policy makers fear that increased pressure to please patients and ensure high satisfaction ratings as a result could lead to overuse of low-value care that doesn t provide any clinical benefit while unnecessarily ratcheting up medical bills.
But new research from the University of Chicago and Harvard Medical School may alleviate some of those concerns. The study, published May 28 in
JAMA Internal Medicine, found no relationship between favorable patient ratings and exposure to more low-value care.
Pandemic has fueled eating disorder surge in teens, adults nwitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nwitimes.com Daily Mail and Mail on Sunday newspapers.
Lifting FDA restrictions on mifepristone could normalize medication abortion
In a new study published online in spring 2021 and in the July issue of the journal
Contraception, University of Chicago Medicine investigators and colleagues interviewed primary care providers in Illinois about their interest in providing medication abortion care and found that lifting FDA restrictions on mifepristone to allow pharmacy dispensing could normalize medication abortion, facilitate its use in primary care facilities, and address disparities in reproductive health access. Mifepristone is used in combination with misoprostol to end early pregnancies, during the first trimester, said senior author Debra Stulberg, MD, MAPP, Chair of the Department of Family Medicine at the UChicago Medicine. The two-drug regimen is safe and highly effective, but access is limited by a strict Risk Evaluation and Mitigation Strategy (REMS) that prohibits pharmacy dispensing of mifepristone.